HOME >> MEDICINE >> NEWS
Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions

SAN DIEGO - The results of a Phase I/II study of NUVANCE™ (IL-4 receptor) in adult patients with moderate asthma will be featured at the Late-Breaker Abstract Session at the American Academy of Allergy, Asthma and Immunology's (AAAAI) 56th Annual Meeting (March 3-8 in San Diego, California).

WHEN: Saturday, March 4, 2000, 3:00 pm

WHERE: Late Breaker: New Therapies Mini-symposium, Room 8, Upper Level of the San Diego Convention Center.

WHO: Dr. Jonathan Corren, MD, Medical Director, Allergy Research Foundation, and lead investigator will present the results of Phase I/II study of NUVANCE™ in adult patients with moderate asthma. Dr. Corren is affiliated with the University of California, Los Angeles.

A presentation entitled, "Cytokines and Cytokine Therapy for Allergic Diseases: Which One is the Most Critical? Il-4 and IL-4 Receptor Antagonists in Allergic Disease," will also be featured at the AAAAI Annual Meeting.

WHEN: Monday, March 6, 2000, 8:45 am - 10:45 am

WHERE: Asthma Therapy Symposium, Marina Ballroom G, Level 3, South Tower, Marriott.

WHO: Dr. Jan Agosti, Medical Director, Immunex Corp., will present scientific evidence and clinical data demonstrating the potential of IL-4 inhibition to improve lung function and control the symptoms of people with asthma.

Interleukin-4 (IL-4) is a naturally occurring cytokine, or immune system protein, that has been commonly associated with the development of asthma and allergies. It binds to specific IL-4 receptors (IL-4R) on the surface of cells in the body or to naturally occurring soluble receptors that circulate throughout the body. Increased levels of IL-4 appear to be related to increased severity of asthma that results in difficulty in breathing. Immunex scientists used recombinant DNA technology to produce a soluble IL-4 receptor, a molecule the company names NUVANCE. When IL-4 binds with NUVANCE instead of cell-surface IL-4R, the effects of IL-4 may be block
'"/>

Contact: Tim Warner
warnert@immunex.com
206-470-4193
Immunex Corporation
1-Mar-2000


Page: 1 2

Related medicine news :

1. Heart transplant survival: Results may be key to rejection prevention, detection, treatment
2. Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial
3. Results from first clinical trial using GVG to treat addiction
4. Results of first chronic treatment study with oral EXANTA(TM) (ximelagatran)
5. Media Advisory-- Results of California autism epidemiology study to be unveiled
6. Results of Yale study confirm aspirin helpful in preventing a first heart attack
7. Yale study shows way to re-stimulate brain cell growth: Results could boost understanding of Alzheimers, other brain disorders
8. Results of NUVANCE phase I/II asthma trial presented
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. UI Study Yields Encouraging Results For New Breast Cancer Treatment
11. Ph.D. Degree Research Results In Patent For Low-Cost Pharmaceutical Filters Made From Seafood Waste

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/8/2019)... ... , ... METAvivor Research and Support Inc., a non-profit organization dedicated to funding ... Stampede campaign. The campaign will commence with two days of action and education on ... camp, a march, a Die-In (hosted by partner MET-UP), and visits with Congressional offices. ...
(Date:10/8/2019)... ... October 08, 2019 , ... The ... a Digital Health Awards 1st Round (Top Ten) Finalist in its Best ... to select companies that promote faster, better, more cost-effective healthcare by improving outcomes ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... dentistry techniques, has recently attended an advanced Level III training in Cagliari, Italy, ... dentistry. The training took place September 16-19, 2019 at the Sardinia Dental Teaching ...
(Date:10/8/2019)... TORONTO (PRWEB) , ... October 08, 2019 , ... ... at a cost of $28 billion per year, are reproducible. Rigor in bioanalytical ... are increasingly outsourced (by some estimates, more than half of the time) and ...
(Date:10/8/2019)... ... October 08, 2019 , ... U.S. Oral ... that exclusively serves premier oral and maxillofacial surgeons – has formed a new ... practice with two locations near Knoxville, Tennessee. The partnership is USOSM’s first in ...
Breaking Medicine News(10 mins):
(Date:10/15/2019)... Ky. (PRWEB) , ... October 15, 2019 , ... Twiggy ... may help those suffering in embittered divorce battles make better decisions and become truly ... Bullying—How to overcome a bully, be resilient, and STOP the cycle! Don’t be a ...
(Date:10/11/2019)... ... October 11, 2019 , ... American Case Management Association (ACMA) ... dedication, compassion and quality patient outcomes achieved by case management professionals across the ... link between patients, providers and payers to improve health outcomes across the care ...
(Date:10/10/2019)... ... October 10, 2019 , ... Ovation Fertility is ... field of reproductive medicine, with six abstracts accepted for poster presentations at the ... for October 12-16, 2019, in Philadelphia. , “Ovation will have a prominent presence ...
Breaking Medicine Technology:
Cached News: